Company partners with Ontario’s Peak Processing to produce high-margin specialty products using terpene-rich biomass, with live resin available for sale in Ontario commencing in May, 2021

WeedMD s pleased to confirm it has closed its previously announced bought deal short-form prospectus offering of 35,937,500 units (“Units”) at a price...

WeedMD announced today that, further to its press release dated February 11, 2021 announcing a $17.5 million bought deal financing, the Company has...

WeedMD announced today that it has amended and re-filed its unaudited reviewed interim financial statements for the three and nine months ended September 30, 2020

Patients may purchase PAX ERA pods in Pedro’s Sweet Sativa cultivar starting March 6th, 2021

Acclaimed Mary’s Transdermal Compound, produced exclusively in Canada by WeedMD, with expected availability to Starseed Medicinal’s patients starting late February, 2021

WeedMD is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, under which Eight Capital has now agreed to...

WeedMD is pleased to announce it has entered into a letter of engagement with Eight Capital, under which Eight Capital has agreed to purchase, as joint...

Terpene-infused Saturday Cannabis 510-thread vapes reach #1 status on Ontario Cannabis Store (OCS) during first month of sales, as product availability expands to retailers and other provinces

Following the fulfilment of its first purchase order to Société québécoise du cannabis (SQDC), the Company and local partner ROSE LifeScience affirm Color Cannabis products now available

As the first Canadian union to actively provide comprehensive medical cannabis coverage, eligible members from LiUNA Local 1258 in Manitoba are now added to the program

Expanded product portfolio using indoor and outdoor-grown, terpene-rich biomass to debut in Q2 2021

Color Cannabis available to consumers in Quebec, one of Canada’s largest markets, via Société Québécoise du cannabis (SQDC) in partnership with local producer ROSE LifeScience.

Company exits Bowmanville facility in 2021 as it implements strategic initiatives and centralizes all cultivation, production and distribution at its London-Area flagship facilities.

WeedMD announced today that Interim Chief Executive Officer George Scorsis issued an open letter to shareholders to provide a corporate overview of WeedMD’s operational and commercial activities.

George Scorsis, WeedMD’s Executive Chairman named interim CEO, taking additional role to lead WeedMD’s accelerated profitability phase in 2021

One-gram 510-thread terpene-infused vaporization products shipping in Ontario by December 31st

First consumer-facing cannabis awards as voted by over 150 Canadian cannabis retail budtenders

Acclaimed strain released via the Ontario Cannabis Store with other provinces coming soon

Reports 8% growth in net revenue quarter-over-quarter for the three months ended September 30, 2020